Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. Antimicrobial stewards seek to achieve optimal clinical outcomes related to antimicrobial use, minimize toxicity and other adverse events, reduce the costs of health care for infections, and limit the selection for antimicrobial resistant strains. Currently, there are no national or coordinated legislative or regulatory mandates designed to optimize use of antimicrobial therapy through antimicrobial stewardship. Given the societal value of antimicrobials and their diminishing effectiveness due to antimicrobial resistance, IDSA supports broad implementation of antimicrobial stewardship programs across all health care settings (e.g., hospitals, long-term care facilities, long-term acute care facilities, ambulatory surgical centers, dialysis centers, and private practices.
IDSA Responds to The Joint Commission's Proposed Standards for Antimicrobial Stewardship for Various Types of Healthcare Facilities (PDF)
IDSA responds to The Joint Commission's Proposed Standards for Antimicrobial Stewardship for various types of healthcare facilities that include Ambulatory Health Care Centers, Critical Access Hospitals, Hospitals, Nursing Homes, and Office-based Surgical Centers.
IDSA and Others Urge CMS to Adopt New Requirements for Stewardship (PDF)
IDSA joins groups representing health care providers, scientists, patients, public health, advocates, and industry in a letter urging the Centers for Medicare & Medicaid Services (CMS) to consider carving novel antibiotics to treat serious or life-threatening infections out of the diagnosis-related group (DRG) and to adopt new requirements for antibiotic stewardship and surveillance.
IDSA Comments to HHS Re Antimicrobial Resistance and the National Biodefense Strategy (PDF)
IDSA supports the National Biodefense Strategy, particulary the goals and objectives related to AMR domestically and internationally, and shared policy recommendations to combat AMR.
IDSA Leads Health Groups in Letter to New Administration Urging Continuation of AMR Efforts (PDF)
IDSA coordinated a letter, joined by 47 other health groups, to President-elect Trump urging that federal efforts to combat antimicrobial resistance be maintained in the years ahead.
IDSA Comments to UN Interagency Coordination Group on Antimicrobial Resistance (PDF)
IDSA submitted comments to the Interagency Coordination Group (ICG) on Antimicrobial Resistance (AMR) established by the UN Secretary-General supporting the objectives set forth by the ICG's proposed work plan, and offering suggestions that would strengthen its efforts.
IDSA Leads Sign On Letter to HHS Secretary on AMR (PDF)
IDSA led a group of over forty organizations representing health care providers, patients, public health, and industry to thank HHS Secretary Tom Price for his upcoming participation in the World Health Assembly, and to continue domestic and international work to advance a robust response to antimicrobial resistance (AMR) that reflects the US commitment to infection prevention, antimicrobial stewardship, surveillance, and innovation.
IDSA Comments to FDA on Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test (AST) Devices (PDF)
IDSA comments to FDA draft guidance on "Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test (AST) Devices to advance AST devices that are necessary for directing the optimal use of antimicrobial drugs.
IDSA Comments to PACCARB (PDF)
IDSA presented comments at a public meeting of the Presidential Advisory Council on Antibiotic-Resistant Bacteria (PACCARB). IDSA applauded the PACCARB for its work so far on the five goals of the National Action Plan for Combating Antibiotic Resistant Bacteria, and highlighted specific recommendations to advance each of the goals in the National Action Plan.
IDSA Comments to PACCARB on Antibiotic Resistance Data Collection (PDF)
IDSA comments to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on challenges faced in gathering and sharing antibiotic resistance data.
IDSA and SHEA Collaboratively Present Evidence and Justification for Antimicrobial Stewardship to be a Medicare Condition of Participation (PDF)
IDSA and SHEA jointly offer the justification and supportive evidence to demonstrate how adopting antimicrobial stewardship (AS) as a Medicare Condition of Participation (CoP) would better patient care, improve outcomes, and lower the healthcare costs associated with antibiotic overuse (i.e. expenditures on antibiotics) as well as costs associated with infections and antimicrobial resistance.
IDSA Leads Groups in Letter to CMS on Stewardship (PDF)
IDSA was joined by 33 other organizations in a letter to the Centers for Medicare & Medicaid Services (CMS) advocating that hospitals and long-term care facilities be required to implement an antibiotic stewardship program (ASP) as a Condition of Participation (COP) in Medicare and Medicaid. CMS is known to be actively considering the proposal. The recommendation was also made by the President's Council of Advisors on Science and Technology (PCAST) in their recent report on combating antibiotic-resistant bacteria.